ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in ...
What the latest Pearson price target tweak really signals Pearson’s base case fair value has been nudged from £12.51 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback